{
    "id": "row_000045",
    "result": {
        "title": "The Essence of Machine and Deep Learning in Pharmacogenomics for Antidepressant Treatment Prediction",
        "introduction": "The application of machine learning and deep learning techniques is becoming a crucial foundation for pharmacogenomics research, particularly in predicting the effectiveness of antidepressant treatments for patients with major depressive disorder (MDD). These advanced computational methods are leveraged to analyze complex biological data, aiming to personalize and improve treatment outcomes.",
        "main_body": "The essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction lies in their ability to serve as a vital foundation for understanding and predicting treatment responses in patients with major depressive disorder (MDD). These techniques are utilized in conjunction with neuroimaging and multi-omics data to achieve several key objectives. Firstly, they are employed to determine treatment prediction, allowing researchers to forecast how a patient might respond to specific antidepressant treatments. Secondly, they help in identifying potential biomarkers, which are measurable indicators of a biological state or condition, that can guide treatment decisions. Through the integration of pharmacogenomics and neuroimaging research, machine learning approaches are used to predict antidepressant treatment outcomes in MDD. Furthermore, in light of advancements in neuroimaging and multi-omics, these algorithms are instrumental in identifying various genomic variants and biomarkers associated with antidepressant treatments in MDD, thereby contributing to a more precise and individualized approach to psychiatric care.",
        "conclusion": "In conclusion, machine and deep learning approaches are essential tools in pharmacogenomics research for antidepressant treatment prediction. They enable the determination of treatment predictions and the identification of potential biomarkers by analyzing diverse data types, ultimately facilitating the discovery of genomic variants and biomarkers crucial for personalizing antidepressant therapies in MDD patients."
    },
    "prompt": "You will be given a JSON object as a string which contains a series of related search queries and their retrieved documents ('hits'). Do not make answer from external knowledge. You must make answer inside of Context.\nYour main task is to answer the specific 'Question' provided below. Use the entire JSON data as context to formulate your answer, paying close attention to the 'text' fields within the 'hits' lists.\n\nThe JSON data has a list of queries. The 'original' query is the one you need to answer. The other queries are supplementary and provide additional context.\nDo not use \"*\", \"-\" symbols. Please don't use \"**\" to emphasize words. Don't answer in markdown format just write it simple.\n\nIf the 'Question' is in Korean, format your answer in Korean as follows:\n##제목##\n\n##서론##\n\n##본론##\n\n##결론##\n\nIf the 'Question' is in English, format your answer in English as follows, If English then Just write title inside of ##{Title}##:\n##{Title}##\n\n##Introduction##\n\n##Main Body##\n\n##Conclusion##\n\n--- Context ---\n{\n  \"id\": \"row_000045\",\n  \"model_name\": \"Alibaba-NLP/gte-multilingual-base\",\n  \"timestamp_kst\": \"2025-09-08T23:55:38.486426+09:00\",\n  \"trial_id\": \"cb56c51c\",\n  \"queries\": [\n    {\n      \"query\": \"What is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?\",\n      \"query_meta\": {\n        \"type\": \"original\"\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.8611539602279663,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    },\n    {\n      \"query\": \"What are the primary challenges in predicting antidepressant treatment response using pharmacogenomic data?\",\n      \"query_meta\": {\n        \"type\": \"single_hop\",\n        \"index\": 0\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.7721887230873108,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    },\n    {\n      \"query\": \"How do machine learning and deep learning approaches help overcome these challenges in pharmacogenomics research for antidepressant treatment prediction?\",\n      \"query_meta\": {\n        \"type\": \"single_hop\",\n        \"index\": 1\n      },\n      \"top_k\": 50,\n      \"hits\": [\n        {\n          \"rank\": 1,\n          \"score\": 0.8618699908256531,\n          \"doc_id\": \"ART002777203\",\n          \"title\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments\",\n          \"abstract\": \"A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\",\n          \"source\": \"http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203\",\n          \"author\": \"nan\",\n          \"embedding_mode\": \"3*title+abstract\",\n          \"embedding_text\": \"Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.\"\n        }\n      ]\n    }\n  ],\n  \"meta\": {\n    \"model\": \"gemini-2.5-flash\",\n    \"temperature\": 0.2\n  }\n}\n\n--- Question ---\nWhat is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?\n\n",
    "model": "models/gemini-2.5-flash",
    "retrival": {
        "id": "row_000045",
        "model_name": "Alibaba-NLP/gte-multilingual-base",
        "timestamp_kst": "2025-09-08T23:55:38.486426+09:00",
        "trial_id": "cb56c51c",
        "queries": [
            {
                "query": "What is the essence of applying various machine and deep learning approaches to pharmacogenomics research for antidepressant treatment prediction?",
                "query_meta": {
                    "type": "original"
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.8611539602279663,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            },
            {
                "query": "What are the primary challenges in predicting antidepressant treatment response using pharmacogenomic data?",
                "query_meta": {
                    "type": "single_hop",
                    "index": 0
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.7721887230873108,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            },
            {
                "query": "How do machine learning and deep learning approaches help overcome these challenges in pharmacogenomics research for antidepressant treatment prediction?",
                "query_meta": {
                    "type": "single_hop",
                    "index": 1
                },
                "top_k": 50,
                "hits": [
                    {
                        "rank": 1,
                        "score": 0.8618699908256531,
                        "doc_id": "ART002777203",
                        "title": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments",
                        "abstract": "A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms.",
                        "source": "http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=ART002777203&target=NART&cn=ART002777203",
                        "author": "nan",
                        "embedding_mode": "3*title+abstract",
                        "embedding_text": "Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments A growing body of evidence now proposes that machine learning and deep learning techniques can serve as a vital foundation for the pharmacogenomics of antidepressant treatments in patients with major depressive disorder (MDD).In this review, we focus on the latest developments for pharmacogenomics research using machine learning and deep learning approaches together with neuroimaging and multi-omics data. First, we review relevant pharmacogenomics studies that leverage numerous machine learning and deep learning techniques to determine treatment prediction and potential biomarkers for antidepressant treatments in MDD. In addition, we depict some neuroimaging pharmacogenomics studies that utilize various machine learning approaches to predict antidepressant treatment outcomes in MDD based on the integration of research on pharmacogenomics and neuroimaging. Moreover, we summarize the limitations in regard to the past pharmacogenomics studies of antidepressant treatments in MDD. Finally, we outline a discussion of challenges and directions for future research. In light of latest advancements in neuroimaging and multi-omics, various genomic variants and biomarkers associated with antidepressant treatments in MDD are being identified in pharmacogenomics research by employing machine learning and deep learning algorithms."
                    }
                ]
            }
        ],
        "meta": {
            "model": "gemini-2.5-flash",
            "temperature": 0.2
        }
    }
}